Abstract | The use of biomarkers is becoming increasingly intrinsic to the practice of medicine and holds great promise for transforming the practice of rheumatology. Biomarkers have the potential to aid clinical diagnosis when symptoms are present or to provide a means of detecting early signs of disease when they are not. Some biomarkers can serve as early surrogates of eventual clinical outcomes or guide therapeutic decision making by enabling identification of individuals likely to respond to a specific therapy. Using biomarkers might reduce the costs of drug development by enabling individuals most likely to respond to be enrolled in clinical trials, thereby minimizing the number of participants required. In this Review, we discuss the current use and the potential of biomarkers in rheumatology and in select fields at the forefront of biomarker research. We emphasize the value of different types of biomarkers, addressing the concept of 'actionable' biomarkers, which can be used to guide clinical decision making, and 'mechanistic' biomarkers, a subtype of actionable biomarker that is embedded in disease pathogenesis and, therefore, represents a potentially superior biomarker. We provide examples of actionable and mechanistic biomarkers currently available, and discuss how development of such biomarkers could revolutionize clinical practice and drug development.
Introduction
A biomarker is a characteristic that can be objectively measured as an indicator of normal or pathologic bio logical processes, or as an indicator of response to therapy.
1 Although commonly used to describe a bio chemical variable, such as the concentration of a circulat ing protein or other biomolecule, this broad definition can apply to many types of biological data. In fact, many biomarker studies focus on anatomical and structural features visualized by conventional radiography, ultra sonography, CT scanning (for example, positron emis sion tomography) or MRI, including functional MRI scans that can provide information about the neuronal activity in certain regions of the brain. 2 Other variables considered biomarkers are cellular immune responses, genetic traits, histologic characteristics of diseased tissue, and proteins or RNA expressed in tissues.
For many diseases, a single biomarker can be informa tive on a population level but not at the level of the individual patient. This inadequacy has shifted atten tion to the use of multiple biomarkers and, in parallel, to the development of technologies for the multiplex measurement of multiple variables. 3 A panel of multi ple biomarkers could comprise different entities of the same type of variable, for example, a number of distinct circulating proteins or expressed genes representing a specific molecular pathway. Alternatively, the panel could comprise a combination of disparate types of features, such as a collection of radiographic, histologic, cellular, proteom ic, and genetic variables.
Herein we review the field of biomarkers in rheuma tology, and the concept of the 'actionable' biomarker. We discuss the superiority of biomarkers that are rooted in the pathogenesis of disease, how these 'mechanistic' bio markers could be most effectively used in clinical practice and in drug development, and how close we are to having such tools for the management of rheumatic diseases.
Actionable biomarkers and their uses
The concept of an actionable biomarker is based on the expectation that results of biomarker testing can be used to guide clinical management of disease. Actionable bio markers can inform clinical practice at many different stages of a disease (Figure 1 ).
Diagnosis of symptomatic disease
The most basic use of an actionable biomarker is in making a clinical diagnosis of symptomatic disease. For example, detection of antibodies directed against specific pathogens indicates the presence of infectious diseases (such as HIV or hepatitis virus), whereas detection of specific genetic aberrations is used in the diagnosis of certain cancers (including myelodysplastic syndrome and chronic myelocytic leukaemia). In rheumatic dis eases, diagnostic biomarkers are also central to clinical practice: the presence of rheumatoid factor (RF) and anti citrullinated protein antibodies (ACPA) aid diagnosis of rheumatoid arthritis (RA); and the presence and specifici ties of antinuclear antibodies (ANA) facilitate diagnosis of systemic lupus erythematosus (SLE). However, unlike in cancer, genetic traits do not seem to be generally useful as diagnostic biomarkers for rheumatic diseases at present.
Key points
■ Biomarkers can aid in the management of disease by facilitating diagnosis and stratification of disease, as well as assessment or prediction of disease severity or response to therapy ■ Drug development can be facilitated by biomarkers that enable selective recruitment of individuals likely to benefit from the intervention being tested or rapid assessment of response to a candidate therapeutic ■ Biomarkers rooted in the mechanism underlying the disease (mechanistic biomarkers) are likely to be more useful than those that are byproducts of the disease process (descriptive biomarkers) ■ Mechanistic biomarkers are more likely to perform better than descriptive biomarkers in differential diagnosis of disease, disease stratification and targeting of treatment, and as surrogate endpoints in clinical trials ■ Cytokines, chemokines, autoantibodies, microRNAs, gene-expression profiles and immune-cell types can all act as mechanistic biomarkers for rheumatic diseases ■ Mechanistic biomarkers might help to establish a molecular taxonomy of diseases
Although specific genetic mutations or polymorphisms are associated with certain autoinflammatory conditions, such as familial Mediterranean fever and MuckleWells syndrome, 4,5 and minor subtypes of certain auto immune diseases, SLE for example, 6 most autoimmune and inflammatory diseases are polygenic, with individual gene polymorphisms conferring only a modest increase in disease risk.
Diagnosis of asymptomatic disease
Beyond their use in diagnosing symptomatic disease, actionable biomarkers can prove informative in the diagnosis of early, asymptomatic disease (Figure 1) . Diagnosing a disease at the asymptomatic stage could enable early therapeutic intervention, with the ultimate goal of preventing the development of symptomatic dis ease or at least limiting the pathologic sequelae of the disease.
7-9 For example, we have identified a profile of serum autoantibodies and cytokines that can be used to identify asymptomatic individuals who will develop RA within 2 years after testing. 10 Prophylactic treatment has the potential to reduce the incidence or severity of RA in this group of individuals, given that current treatments result in impressive clinical and radiological improve ments when used to treat recentonset, symptomatic RA. 11 Likewise, specific autoantibodies can be detected in the blood of individuals who will go on to develop symptomatic SLE, 7 which might prove useful in guiding prophylactic treatment of this disease.
Assessment and prediction of disease activity
Biomarkers that aid assessment of disease activity are useful because they can reveal the presence or pro gression of disease despite the remission of symptoms. For example, such biomarkers are especially needed for osteo arthritis (OA), for which few, if any, disease modifying therapies exist. Routine radiography, the current standard means of assessing OA, is not a sen sitive enough tool for identifying changes that foretell cartilage and bone abnormalities or pathologic fea tures that differen tiate mechanistically distinct subsets of OA. Structural and anatomical features assessed by MRI, such as articular cartilage integrity, bone marrow lesions, synovitis, and osteophytes, are being developed as biomarkers of disease activity in OA and have the potential to be used as surrogate endpoints in earlystage trials. [12] [13] [14] Cartilage oligomeric matrix protein, a product of cartilage turnover, and metabolomic profiles are also being explored as potential biomarkers for assessment of disease activity in OA. [15] [16] [17] Prognostic biomarkers predict severity of disease and, therefore, can guide the selection of an appropriate thera peutic regimen by providing information as to whether the disease is likely to be selflimiting or to develop into a severe form. Although several prognostic biomarkers, such as erythrocyte sedimentation rate (ESR), Creactive protein (CRP), complement proteins C3 and C4, and anti DNA antibodies, are currently used in the management of rheumatic diseases, the sensitivity and specificity of these biomarkers in predicting the course of disease are Figure 1 | Possible clinical uses of actionable biomarkers at different stages of the development of RA. Screening the asymptomatic, at-risk population for biomarkers of RA-associated asymptomatic autoimmunity could identify individuals who will go on to develop RA, before they develop symptomatic disease. Profiling RA-associated biomarkers in individuals with undifferentiated arthritis who present with synovitis could enable the early diagnosis of RA, before the ACR criteria for a diagnosis of this disease are met and before cartilage and bone erosion has begun. Prognostic biomarkers could also enable the severity of disease course to be predicted in individuals with undifferentiated arthritis. Biomarkers could guide the selection of appropriate therapy by predicting disease activity and progression, by predicting which individuals will respond to a particular therapy, and by providing pharmacodynamic information to facilitate assessment of response to therapy. At each of these stages, biomarker profiling can inform physicians on how best to manage their patients to slow or even stop the progression of disease. Abbreviations: ACR, American College of Rheumatology; RA, rheumatoid arthritis.
suboptimal. 18 Profiles of inflammatory molecules are being developed as prognostic biomarkers for RA; 19 although such multibiomarker panels have been shown to correlate closely with disease activity, 18 their specificity for RA (rather than other inflammatory and auto immune diseases) remains to be fully assessed.
Dynamic biomarkers
In disease progression or response to therapy Another actionable use of biomarkers is monitoring the progression of disease or response to therapy. Such 'dynamic' biomarkers can facilitate prediction of the ultimate clinical outcome by reporting early changes in diseaseassociated biological processes. Results of dynamicbiomarker profiling could prompt the clinician to initiate or intensify therapy in the setting of highly active disease or, conversely, to withdraw a specific treatment in the setting of an insufficient therapeutic response. For example, in nonrheumatic diseases, serum levels of prostatespecific antigen and αfetoprotein can be informative in assessments of response to therapy in prostate cancer-for cases with abnormally high levels of this protein at the time of diagnosis-and hepato cellular cancer, respectively. 20 Likewise, serial assessment of tumour size by semiquantitative imaging is a standard of care in the treatment of many solid cancers. Examples of dynamic biomarkers for rheumatic diseases include ESR in polymyalgia rheumatica, 21 and a profile of inflam matory mediators that reflects disease activity in RA. 19 In addition, levels of proteinuria and composition of urine sediment are both used in assessing response to therapy in SLE. 22 As routine imaging in rheumatology moves beyond conventional radiography, which predominantly reveals irreversible structural changes, to technologies such as MRI 23 or ultrasonography 24 that enable serial assessment of synovitis, the results of interval imaging will probably become a commonly accepted dynamic biomarker of disease activity.
Beyond clinical practice, pharmacodynamic bio markers that serve as surrogate endpoints-described by the FDA as biomarkers that can substitute for a clinical endpoint that "reflects how a patient feels, functions, or survives" 25 -can be useful in drug development. Such biomarkers can provide insight into whether a therapy will be effective early in the development process; thus, time and resources spent on investigational drugs that will ultimately prove ineffective are minimized, enabl ing resources to be refocused on the development of a wider range of alternative potential therapies. Indeed, the identification of pharmaco dynamic biomarkers that can provide early proof of concept is one of the research areas prioritized by the FDA's Critical Path Initiative. 26 Pharmacodynamic biomarkers have, in fact, been incor porated into the study of drugs for rheumatic diseases for decades. Even in early studies, identification of a decrease in serum levels of IL1 in response to metho trexate 27 and a reduction in levels of CRP after inflixi mab treatment provided proofofconcept supporting what are now well established therapies for RA. 28 More recently, a decrease in the number of macrophages in the sublining of synovial tissue obtained by needle biopsy has been proposed as an early biomarker of therapeutic efficacy in RA. 29 In addition, profiling the expression of genes associ ated with the type I interferon (IFN) pathway in blood and skin samples has yielded proofofconcept data in trials of antiIFN antibody therapy in SLE 30 and might do the same in future therapeutic trials in systemic sclero sis. 31 Nonetheless, pharmacodynamic biomarkers are used primarily to guide drug development, with clinical endpoints still forming the basis of regulatory approval. 25 
Assessment of drug toxicity
The use of pharmacodynamic biomarkers in drug develop ment can also enable early detection of drug related toxicity. The failure rate of novel investiga tional drugs in phase II and phase III clinical trials now approaches 85% and 50%, respectively, and, at each phase, adverse events and safety concerns account for approximately 20% of these failures. 32, 33 Examples of dynamic bio markers of toxicity include traditional labo ratory variables, such as biochemical indicators of liver and kidney dysfunction, but also surrogates of cardiac toxicity, such as increased blood pressure, an increase in levels of serum lipids and prolongation of the QT inter val on an electrocardiogram. Going forward, it will be important to identify 'nextgeneration' biomarkers that can serve as early indicators of toxicity or other adverse events in clinical trials.
Predictive biomarkers

Predicting responsiveness to therapy
In contrast to pharmacodynamic biomarkers, which reflect the response to therapy, predictive biomarkers can be used to predict responsiveness to therapy before therapy is initiated. Matching the right drug with each individual is important because a particular treatment will benefit only the subset of patients in whom the mechanism the drug targets is active. Thus, the ability to identify the individuals most likely to respond to a particular therapeutic would greatly benefit patients, pre venting those who would not respond from experienc ing drugrelated adverse events and incurring the costs of a treatment that is ineffective. The benefits of a targeted approach to therapy would also have considerable soci etal implications: improved drug development, achieved through the testing of candidate therapeutics only in patients likely to benefit, 34 would optimize use of limited healthcare resources; and a decrease in adverse effects of treatment would improve patient outcomes.
Biomarkers predictive of responsiveness to therapy have already proven invaluable in the treatment of several types of cancer. For example, expression of the estrogen receptor is indicative of responsiveness to hor monal therapy in breast cancer, 35 the presence of the BCR-ABL1 translocation indicates responsiveness to the tyrosine kinase inhibitor imatinib in chronic mye locytic leukaemia, 36 and overexpression of the receptor tyrosineprotein kinase ErbB2 (also known as HER2) indicates responsiveness to specific antiErbB2 mono clonal antibodies (trastuzumab, pertuzumab) and to tyrosine kinase inhibitors (lapatinib) in breast cancer. 37 Other bio markers that enable targeted therapy are speci fic mutations in the KRAS gene, which in lung and colo rectal cancers indicate a lack of responsiveness to tyrosine kinase inhibitors targeting the epidermal growth factor receptor. 38 Although most rheumatic diseases are more molecularly hetero geneous than the malig nancies dis cussed, evidence suggests that blood plasmablast levels, determined by measuring IgJ mRNA expression, could serve as biomarkers of responsiveness to Bcelldepletion therapy in patients with RA; 39 however, the association is not as strong as for the described genetic mutations in cancer. 40, 41 In addition to their use in clinical practice, bio markers predictive of responsiveness to therapy have great potential in improving the drug development process. Predictive biomarkers can reduce the size of the cohorts needed in clinical trials by enabling selec tive recruitment of participants who are likely to benefit from the intervention being tested, thereby substantially reducing costs, stream lining clinical development, and, importantly, reducing exposure of individuals unlikely to respond. However, considerable costs are associated with the develop ment of a 'companion diagnostic' biomarker for clinical trials that accurately identifies patients who are likely to respond to treatment; if a clear mechanistic biomarker is not available, the added costs and logistical and regulatory complexity can, in certain cases, outweigh the potential benefits. Nevertheless, the FDA has under taken initiatives to facilitate the collaborative develop ment of biomarkers and thereby lessen the resource burden on any individual, organization or company working towards qualification of a biomarker for use in drug development. 25 Thus, as the cost of drug develop ment soars, 42 we believe that integrated use of predictive and pharmaco dynamic bio markers represents an impor tant strategy for controlling costs and ex pediting clinical development programs.
Descriptive and mechanistic biomarkers
Biomarkers do not need to be directly involved in disease pathogenesis to be useful, though a biomarker is likely to be more informative if it has some mechanistic involve ment. For example, ESR and CRP are components of the dis ease activity score (DAS), 43 which is used in assessing dis ease activity in RA. Nevertheless, ESR and CRP are not specific to RA: they are markers of inflammation that are also associated with many other rheumatic and non rheumatic inflammatory disorders, including infection, malignancy and even coronary artery disease. Such bio markers are referred to as descriptive biomarkers because they describe the state of a disease but are not involved in the pathogenesis of the disease. Many descriptive bio markers are associated with a disease because they are products of the disease process or of diseaseinduced damage; such factors are byproducts rather than intrinsic players in disease pathogenesis. Therefore, only limited pharmacodynamic, diagnostic or prognostic information can be derived from descriptive biomarkers, 18 restricting their usefulness.
The most informative actionable biomarkers are rooted in the mechanism underlying the disease (Figure 2 ). Mechanistic biomarkers are superior to descriptive bio markers for a number of reasons (Figure 3 ). First, a bio marker directly involved in the patho genesis of the dis ease is more likely to be specific to that disease, com pared with a descriptive biomarker that is a byproduct of the disease process, and therefore performs better in the differential diagnosis of disease. Second, mecha nistic biomarkers often enable differen tiation of dis tinct subtypes of the same disease and can, therefore, be used to stratify disease and target treatment. Third, a pharmaco dynamic biomarker that is mechanistic can reliably reveal whether a therapy is efficaciously target ing the cause of a disease, rather than simply improving the symptoms of a disease, and thus represents the most useful type of biomarker for informing the development and expediting the assessment of rationally designed, mechanismbased therapies.
In recognition of the importance of mechanistic bio markers in drug development, increasing effort is put into integration of molecular diagnostics with therapeu tics technologies. 44 Researchers have even begun per forming pathwaybased biomarker discovery. Whereas the traditional paradigm of biomarker discovery involves seeking variables associated with a disease or clinical outcome and then evaluating the biological plausibility of candidates identified, in the pathwaybased approach a signature of a pathway or process thought to be involved in the disease is tested for association with the disease or clinical outcome. 45 For example, a pathwaybased approach was used in identifying a geneexpression bio marker that can predict survival of individual women with breast cancer; 45 in this case, wound healing was the mechanism assumed to be important (Table 1) . 45 A geneexpression signature of wound healing was experi mentally derived in vitro, and a correlation score was developed for assessing how closely the geneexpression profile of a tumour specimen matched the wound healing signature. 45 This correlation score was able to accurately predict which women with breast cancer did not need adjuvant chemotherapy. 45, 46 Another example of pathwaybased biomarker discovery is the derivation of a geneexpression signature in skin biopsies that identifies cases of systemic sclerosis that are driven by the tyrosine kinases plateletderived growth factor receptor and Abl and are, therefore, likely to respond to treatment with the tyrosine kinase inhibitor imatinib. 47 Clear examples of mechanistic biomarkers include those we have discussed: the BCR-ABL1 translocation in chronic myelocytic leukaemia, and the overexpression of the ErbB2 in breast cancer. Rooted in the disease mecha nism, these biomarkers not only stratify disease but also provide a basis for selecting mechanismbased therapies. Allergy skin testing is another example of the use of mechanistic biomarkers: known allergens are injected subcutaneously, and development of an immune response to one of the allergens indicates that the person being tested is allergic to that particular allergen. Thus, the controlled immune response serves as a mechanistic biomarker of a specific allergy and provides informa tion that can guide the development of antigenspecific toleriz ing immunotherapy. The current status of mecha nistic biomarkers for rheumatic diseases is discussed in the following sections.
Mechanistic biomarkers in rheumatology
Cytokines and chemokines A clinical disease category (RA or SLE, for example) often comprises several distinct disease subtypes that can differ subtly in clinical presentation but markedly in molecular phenotype. Understanding the molecular pathogenesis of disease is essential for development of mechanistic biomarkers, a concept illustrated by findings of research in multiple sclerosis (MS). Although a common treat ment for MS, IFNβ is not efficacious in 30-50% of cases. A recent study showed that a form of mouse MS driven by type 1 T helper (T H 1) cells responded to IFNβ treat ment, whereas a form of the disease driven by type 17 T helper (T H 17) cells did not and was, in fact, exacerbated by the treatment. 48 Moreover, a followon study showed that IL7 promoted T H 1celldriven, but not T H 17cell driven, autoimmune demyelinating disease, and that high levels of IL7 in the blood of individuals with relapsing remitting MS were predictive of responsiveness to IFNβ therapy. 49 Thus, identifying the molecular mechanisms of disease revealed biomarkers directly involved in patho genesis of the disease that might prove useful in guiding personalized clinical care.
In rheumatology too, efforts are increasingly being made to use our advancing knowledge of molecu lar pathogenesis to identify mechanistic biomarkers (Figure 2 ). This approach has been used to search for biomarkers for autoinflammatory diseases known to be driven by IL1, such as familial Mediterranean fever, Muckle-Wells syndrome and the related cryopyrin associated periodic fever syndromes, and systemic onset juvenile idiopathic arthritis. 50 However, neither levels of IL1 in the blood nor levels of IL1 derived from periph eral blood mononuclear cells (PBMCs) activated ex vivo can accurately predict the response of these diseases to IL1blocking therapy; 51 biomarkers downstream of IL1, such as IL1induced transcriptional profiles, 52 are now being assessed as potential biomarkers for these au toinflammatory diseases.
More advanced is the search for mechanistic biomark ers for SLE, which centres on type I IFNs. Type I IFNs have an important role in SLE pathogenesis, 53 and indivi duals with SLE have abnormally high levels of type I IFNs in their blood, 54 as well as a signature of type I IFN associated gene expression in their circulating immune cells. 55 Measuring type I IFN directly is challenging because many different IFN isoforms exist; therefore, levels of transcripts induced by type I IFNs are measured Figure 3 | Types and uses of descriptive and mechanistic biomarkers for autoimmune rheumatic diseases. Mechanistic biomarkers are embedded in the pathogenesis of the disease and, thus, are generally more informative and more accurately reflect the disease state compared with descriptive biomarkers, which are byproducts of the disease process. The predictive or dynamic nature of mechanistic biomarkers offers clear advantages for disease diagnosis, prognosis and management, as is clear from the list of their uses. Genetic traits could serve as mechanistic biomarkers that are useful for diagnosis, prognosis or prediction of responsiveness, but not for assessment of disease progression or response to therapy; that is, they cannot serve as dynamic biomarkers. Abbreviations: CRP, C-reactive protein; DEXA, dual-energy X-ray absorptiometry; ESR, erythrocyte sedimentation rate; SAA, serum amyloid A.
as surrogates for the levels of type I IFN. Increased levels of these transcripts are associated with SLE disease activ ity. 56 Indeed, transcriptional profiles of genes induced by type I IFNs are already being used as surrogates of disease activity in earlyphase clinical trials 30 and could prove to be actionable, mechanistic biomarkers for SLE.
Another cytokine that could serve as a mechanistic biomarker is CXC motif chemokine 13 (CXCL13; also known as B lymphocyte chemoattractant; Table 1 ). CXCL13 has an essential role in organizing germinal centres, and high expression of CXCL13 mRNA in the inflamed RA synovium is a strong predictor of the presence of germinal centres in this tissue, 57 suggest ing that CXCL13 contributes to the autoimmune syn ovitis in RA. In addition to B cells, osteoblasts express the receptor for CXCL13, and activation of this recep tor induces osteoblasts to release extracellularmatrix degrading enzymes, 58 suggesting that CXCL13 also contributes to bone remodelling in RA joints. Indeed, in silico model ling of an RA joint, taking into account synovitis, cartilage destruction and bone erosion, iden tified CXCL13 as a candidate prognostic biomarker of erosiveness, 59 further implicating CXCL13 in the patho genesis of RA. That CXCL13 might be a useful mechanis tic biomarker has so far been borne out by the findings of studies in patients with RA. The findings suggest that high levels of serum CXCL13, which positively corre late with levels of synovial CXCL13 expression, 60 could serve not only as a biomarker of active disease but also as a biomarker predictive of severe RA. 59, 61, 62 Moreover, assessment of the usefulness of CXCL13 as a pharmaco dynamic biomarker showed that serum levels of CXCL13 decreased after TNF blockade, correlating positively with changes in DAS28 (disease activity score using 28 joint counts). 62 Finally, high levels of serum CXCL13 were pre dictive of a faster rate of Bcell repopulation after rituxi mab therapy in patients with RA. 60 Whether CXCL13 will prove useful in the clinic or in drug development depends on whether levels of this chemokine can be reli ably detected in blood samples and on its sensitivity and specificity as a biomarker.
Autoantibodies
Autoantibodies are emerging as useful, possibly mecha nistic, biomarkers for autoimmune rheumatic diseases. Autoantibodies that bind to and form immune complexes with DNA, RNA or chromatin autoantigens implicated in SLE augment type I IFN production in plasmacytoid dendritic cells by providing a second stimu latory signal that synergizes with the signal delivered by the auto antigen. The autoantibodies in the immune complexes activate Fcγ receptors on the cell surface, after which the autoantigens are internalized and directly activate Toll like receptor (TLR) 9 (in the case of a DNA auto antigen) or TLR7 (in the case of an RNA auto antigen). [63] [64] [65] [66] [67] [68] Indeed, autoantibodies that target RNAbinding pro teins (such as Ro and La antigens, and U1 small nuclear ribonucleo protein A) or DNA are associated with increased serum IFNα activity-determined using an in vitro reportercellbased assay of IFNinduced gene expression)-in patients with SLE. 69 Autoantibodies in immune complexes can likewise augment the ability of the correspond ing autoantigen to activate autoreactive B cells by triggering Bcell receptor signalling, which syn ergizes with TLR9 or TLR7 signalling in inducing the production of autoantibodies. 66 In RA, ACPA autoantibodies target a wide variety of citrullinated antigens, including citrullinated fibrinogen. Although citrullinated fibrinogen alone can induce the production of the inflammatory cytokine TNF by acti vating TLR4, citrullinated fibrinogen bound to auto antibodies induces TNF production by macrophages more effectively through the synergistic activation of both TLR4 and Fcγ receptors. 70 Together, these findings suggest that autoantibodies targeting immunologically active autoantigens (such as DNA, RNA, chromatin, cit rullinated fibrinogen) could be pathogenic by augment ing the activation of specific molecular pathways that underlie disease pathogenesis. Thus, such auto antibodies could themselves be considered mechanistic biomarkers. Abbreviations: ACPA, anti-citrullinated protein antibodies; ANA, anti-nuclear antibodies; CXCL13, C-X-C motif chemokine 13; ErbB2, Receptor tyrosine-protein kinase ErbB2; IFN, interferon; MS, multiple sclerosis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; T H 1, type 1 T helper; T H 17, type 17 T helper.
If such autoantibodies are found to contribute to disease pathogenesis, autoantibody profiling in atrisk individuals could be useful for diagnosis of disease before the onset of symptoms (Table 1) . Indeed, autoantibodies are present in the blood long before the clinical onset of many autoimmune diseases, including SLE, 7 MS, 8 type 1 diabetes mellitus, [71] [72] [73] and RA. 74, 75 Likewise, increases in the levels of cytokines 76, 77 and acutephase reactants 78 in the blood occur before the onset of clinical disease in RA. Moreover, accumulating evidence indicates that the range of different autoantibodies present and levels of specific autoantibodies increase as the onset of clinical disease approaches. 8, 10, 72 Besides aiding in the prediction of clinical disease onset, profiling pathogenic autoantibodies could be used to guide therapy. Autoantibody profiling can identify the critical antigens targeted by the diseaseassociated immune response and thereby guide the development of tolerizing therapies, an approach that has been used for MS. 79, 80 Autoantibody profiling could also guide early or preventive intervention; in RA, for example, metho trexate treatment markedly decreased the incidence of progression from undifferentiated arthritis to clinical RA in a randomized, placebocontrolled trial, but this effect was only in the ACPA + population. 81 Thus, profil ing ACPA represents an example of an actionable, mecha nistic biomarker that could guide early or even preventive intervention in RA. Furthermore, identifying the speci fic ACPA present during the asymptomatic phase 10, 76, 77 could not only improve the identification of those at risk of developing clinical RA but also pinpoint the time closest to the onset of clinical RA-a time at which the disease might be most amenable to immuno modulatory intervention. Finally, one can en vision performing diag nostic tests for autoantibodies targeting immunologically active autoantigens and then using this information to select a therapy that targets the downstream mediators of the specific pathways activated in an individual patient (for example, therapies targeting IFNα, TNF, IL6, IL1, IL17, or IL12p40).
Not only autoantibodies but also antidrug antibodies (ADA) could serve as mechanistic biomarkers. Certain individuals develop ADA against biologic therapeutics; 82 depending on their specificity, these ADA can neutralize or otherwise interfere with the activity of the biologic agent, affect the rate at which the drug is cleared from the body, or trigger serious adverse effects by crossreacting with self proteins. Biologically active ADA could thus serve as mechanistic, pharmacodynamic biomarkers that are an early sign of a lack of response or of an adverse response to a biologic therapeutic.
MicroRNAs
An emerging concept is the potential of micro RNAs (miRNAs) to serve as biomarkers for rheumatic dis eases. 83, 84 A single miRNA can regulate the translation of multiple genes and thus have farreaching biological effects. Of particular interest in rheumatology is miR146a, which has important roles in the control of inflammation and immunity. Expression of miR146a is induced during activation of T cells, in which it suppresses apoptosis and IL2 production. 85 A reduction in apoptosis of inflam matory cells, including T cells, is a feature of RA, 86 and miR146a expression is, in fact, upregulated in IL17 expressing T cells, macrophages and B cells in the RA synovium. 87, 88 Moreover, miR146a expression is upregu lated in PBMCs of individuals with RA, 88, 89 and miR146a expression was found to be increased in the synovium of individuals with greater disease activity in a study that enrolled a small number of patients with RA (n = 6). 88 miR146a is also overexpressed in PBMCs from indivi duals with Sjögren's syndrome. 90 Conversely, miR146a expression is downregulated in PBMCs from patients with SLE, and the level of this microRNA in these cells corre lates inversely with disease activity and with the expression of IFNinducible genes implicated in SLE pathogenesis. 91 Another miRNA that shows promise as a biomarker is miR155. This miRNA promotes the development of inflammatory T H 1 cells and T H 17 cells and Tcell dependent tissue inflammation, 92 key processes in the pathogenesis of RA. Indeed, miR155 knockout mice were resistant to development of collageninduced arthritis, producing markedly fewer autoreactive B cells and T cells in response to immunization with collagen, and were partially protected from bone erosion in the K/BxN serumtransfer model of RA owing to a decrease in osteoclast formation. 93 Furthermore, miR155 expres sion is upregulated in PBMCs from patients with RA. 89 Together, these findings suggest that miRNAs might prove to be mechanistic biomarkers of rheumatic dis eases, and increasing efforts in this area are uncover ing further miRNAs that could fulfill such a function. 84 Nevertheless, the clinical utility provided by miRNA biomarkers will depend on their predictive value and whether they can be reliably detected in blood samples.
Future of biomarkers in rheumatology
Despite the current paucity of definitive mechanistic bio markers for rheumatic diseases, a deeper understanding of disease pathogenesis is starting to uncover putative mechanistic biomarkers (Table 1) , as well as identifying mechanistic roles for certain known biomarkers. In the future, biomarkers might help to establish a molecular taxonomy of diseases that are currently classified accord ing to phenotype alone. Most rheumatic diseases are cur rently diagnosed on the basis of medical history, clinical findings, and basic laboratory tests, all of which reflect the phenotype but not the underlying molecular pathol ogy. Given the wide heterogeneity in disease course, diseaserelated damage and response to therapy, defining the molecular features of rheumatic diseases, and thus establishing a molecular taxonomy of the diseases and their subtypes, is essential. Among rheumatic diseases, molecular characterization is perhaps most advanced in RA, which can already be divided into ACPA -and ACPA + subtypes, with the latter generally representing the more severe form of disease. 94 As a means of iden tifying further molecular markers capable of classifying and stratifying rheumatic diseases, the field has begun to uncover the primary inflammatory drivers of such conditions and their subtypes. For example, IL1 is the main driver of inflammasomemediated diseases, includ ing several autoinflammatory diseases, gout and possibly pseudogout, and these conditions are responsive to IL1 antagonism. 95 By contrast, RA is only minimally respon sive to IL1 antagonism and less than half of patients with RA respond to TNF antagonism.
In addition to inflammatory cytokines, different immunecell types can also distinguish different sub types of the same clinical disease. Focusing on cell types as stratifying biomarkers is a relatively new area of bio marker research, best exemplified by the classification of MS according to whether disease is driven by T H 1 cells or by T H 17 cells. 48 Although IFNβ treatment (which is effec tive in T H 1celldriven but not T H 17celldriven MS) 48 improved disease outcomes in animal models of RA, 96, 97 this therapeutic was not efficacious in clinical trials of patients with RA, 98 suggesting that other molecu lar path ways are driving pathogenesis in this disease. SLE might, likewise, comprise different subtypes distinguished by the involvement of distinct immunecell types. As the main producers of type I IFN, plasmacytoid dendritic cells make an important contribution to the pathogenesis of SLE; however, T cells, B cells and neutrophils are also involved, such that the type I IFN signature might serve as an actionable biomarker only in a subset of patients with SLE. 99 A growing area of biomarker research in rheumatology, and particularly in RA, is the search for bio markers that can predict successful drugfree remission. An increas ing number of patients with RA achieve longterm clinical remission whilst being treated with DMARDs in clini cal trials, and focus is increasingly placed on determin ing whether such patients can remain in remission once they stop taking these therapeutics-that is, whether they can achieve 'true' drugfree remission. Find ings suggest that drugfree remission is achieved in 17-29% of patients with RA and that most patients who have to restart medication are able to once again achieve medi cated remission. 100 Nonetheless, because some patients do not achieve remission upon restarting medication, pre dictors of success ful drugfree remission are needed. At present, ACPA negativity, sharedepitope nega tivity and short duration of symptoms before initiation of treatment have been identified as predictors of drugfree remis sion in RA, but longer followup after treatment cessa tion is needed and could unearth additional and better pr edictive biomarkers. 100 Stratifying diseases classified according to pheno type is not the only way that biomarkers can be used to forge a molecular taxonomy of disease: they can do so also by breaking down the boundaries of current clas sifications. That is, biomarkers can be used to uncover molecular similarities between diseases thought to be distinct. For instance, the type I IFN signature is asso ciated not only with SLE, but also with dermatomy ositis and poly myositis, 101 Sjögren's syndrome, 102 and some cases of systemic sclerosis. 103 Thus, this signature might serve as an actionable biomarker for multiple autoimmune pathologies.
Conclusions
For each of the rheumatic diseases, great opportunity exists for identifying actionable biomarkers, whether based on imaging, profiling of autoantibodies, measur ing levels of inflammatory mediators or other molecular analyses. The shortcomings of many biomarkers cur rently used in the diagnosis and management of the rheumatic diseases, at least relative to those available for certain cancers discussed in this Review, is that they are not related to the underlying disease mechanism. Thus, stratifying current clinical classifications and identify ing molecular pathways that mediate the pathogenesis of disease represents an important first step towards defining a new molecular taxonomy of disease and the subsequent identification of diagnostic, predictive and prognostic mechanistic biomarkers. We anticipate that involvement of certain molecular pathways will be shared across subsets of multiple different rheumatic dis eases, whereas other pathways will be diseasespecific. Molecular classification of disease could enable the identification of disease subtypes that are responsive to specific therapeutics and eventually the use of patient derived biomarkers for guiding targeted therapy.
As a field, rheumatology has long been at the forefront of biomarker discovery; some of the biomarkers identi fied will prove to be descriptive whereas others could prove to be mechanistic. Nevertheless, as our understand ing of the molecular immunology of rheumatic disease progresses, we envision a future with biomarkerbased molecular subtyping of disease that can guide clinical decision making.
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